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PRM98
HEALTH ECONOMIC EVALUATION OF DIAGNOSTIC AND PROGNOSTIC 
PREDICTION MODELS. A SYSTEMATIC REVIEW
Van Giessen A1, Wilcher B.2, Peters J.2, Hyde C.2, Moons K.G.1, de Wit G.A.3, Koffijberg H.1
1University Medical Center Utrecht, Utrecht, The Netherlands,, 2Exeter University, Exeter, UK, 
3National Institute for Public Health and the Environment, Bilthoven, The Netherlands
Objectives: The aim of this study is to provide an overview of the quality of health 
economic evaluations (HEEs) of prediction models, the evidence used, and the chal-
lenges. MethOds: The databases Medline, Embase, Econlit, and the NHS Economic 
Evaluations Database were systematically searched for HEEs of diagnostic and prog-
nostic risk prediction models. The included HEEs were evaluated on their meth-
odological quality using the Drummond checklist. Furthermore, an item list was 
developed incorporating descriptive items on the HEE, specific items on the HEE of 
prediction models, and statistical characteristics of the prediction model that could 
be incorporated into the evaluation. Results: The database search resulted in 791 
unique papers, from which 653 were excluded based on abstract. After assessing 
full texts, 17 HEEs (all cost-utility studies) were included. A prediction model was 
compared to current practice in 11 HEEs and to an extended prediction model in 6 
HEEs. On a 35-point scale the quality score ranged from 17 to 32 (median 25). In 7 
papers there was no overlap between authors of the initial prediction model paper 
and those of the corresponding HEE. In 5 papers individuals were classified based 
on a single (set of) threshold(s); based on guidelines in 4 papers and once on expert 
opinion. In 8 papers the classification threshold was optimized in the CEA itself. 
A probabilistic sensitivity analysis was not included in 7 papers and uncertainty 
around predicted risks was only taken into account once. cOnclusiOns: In most 
papers limited (prediction model) details were available. Potentially due to this lack 
of evidence and a lack of specific guidelines on HEE of prediction models, a large 
variety in the quality and methodology was observed. This variation may complicate 
the validation and interpretation of HEE results and thereby the decision making 
on implementation of prediction models in practice.
PRM99
MIGRATION OF HEALTH ECONOMICS MODELS TO WEB AND MOBILE 
ENVIRONMENTS. WHY SHOULD MODELS GO WEB?
Topachevskyi O.1, Volovyk A.2
1Digital Health Outcomes, Brussels, Belgium, 2Hashtago, Kiev, Ukraine
Objectives: To understand the key functional differences between conventional 
cost-effectiveness Excel and web based model types. MethOds: An online survey 
consisting 18 end users and 5 model owners (n= 23) was conducted. Respondents 
were asked to rate key criteria of both model types on a scale from 0 to 10. Model 
types were compared with the following 13 criterias: model execution speed and 
size, general functionality support, accessibility, usability, model management and 
versioning, ease of localization, ease of model core modification, sharing, review 
process, usage analytics, integration with other content. No weighting to the scor-
ing across criteria was applied. Results: Results of the survey indicate that web 
based models outperform standalone models in 10 of the 13 criteria assessed. Model 
review process, ease of model core modification and execution speed was rated 
higher for conventional standalone Excel models. 80% of model owners and 78% of 
model users assigned higher overall score for web based models compared to Excel 
models. cOnclusiOns: Web based models offer advantages primarily related to 
model usage and lifecycle management. These models can be viewed on any hard-
ware device or browser, thus overcoming the limitations of Excel models. The use of 
latest web technologies such as JavaScript, HTML5 and CSS3 improve user experi-
ence in model adaptation and presentation to end audience. Usage analytics, smart 
versioning, web sharing and automatic updates are the functional advantages that 
can not be achieved with conventional Excel models due to technical limitations.
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VALIDATING A MODEL TO PREDICT DISEASE PROGRESSION OUTCOMES IN 
PATIENTS WITH COPD
Risebrough N.A.1, Briggs A.2, Baker T.M.3, Exuzides A.4, Colby C.4, Rutten van-Molken M.5, 
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Objectives: To validate a model for quantifying the COPD disease progression 
against both the data used to generate the model (internal validation) and clinical 
trial data not used in the model’s development (external validation). MethOds: 
A model representing causal relationships between central disease attributes 
(lung function, exacerbations, symptoms and exercise capacity) and final out-
comes (survival, quality of life, cost) was developed based on the Evaluation of 
COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study 
dataset. Model predicted annual outcomes were compared to the corresponding 
annual observed data from ECLIPSE (n= 2,164) and TOwards a Revolution in COPD 
Health (TORCH) (n= 6,108) trials based on fitting the model baseline parameters to 
reflect each specific study population. Results: The model accurately predicted 
the ECLIPSE outcomes in at least two of the three annual time points within the 
95% confidence interval (CI) of the observed data for survival, FEV1% predicted, 
and annual exacerbations (per patient per year [PPPY]. The model predicted 9.0 
metres annual decline in Six Minute Walk Distance compared to ECLIPSE observed 
data of 5.7 metres decline. The model accurately predicted the TORCH placebo 
outcomes in at least two of the three annual time points within the 95%CI of the 
observed data for FEV decline and annual exacerbations PPPY. The model over 
predicted survival by 8% (absolute) compared to TORCH observed data at year 
3. cOnclusiOns: As expected, the model more accurately predicted the ECLIPSE 
observed outcomes in the internal validation exercise, than TORCH outcomes in 
the external validation.
years (QALYs). Thus, considerations on QoL outcomes in the clinical trial design 
phase may lead to better optimized reimbursement submissions. The objective 
of this study was to develop a trial simulation model that is capable of addressing 
complex research questions, provides flexibility to test various assumptions, and 
predicts expected QALY outcomes. MethOds: A patient-level simulation model 
was developed using hypothetical data in oncology. The model considered two treat-
ments reflecting the common design of a pivotal trial. Individual survival times 
and time to progression data were simulated. Hazard ratios were used to include 
treatment effects. Using the simulated individual level data, a multistate life table 
model was constructed with three health states: pre-progression (with and without 
adverse events), post-progression, and dead. Utility and disutility values derived 
from literature were attached to the number of patients in each health state at a 
given point in time. Differences between the treatment arms were derived in terms 
of survival, QALYs, and the uncertainty around those (e.g. probability distribution, 
P-value). Results: The trial simulation model assessed various patient number 
scenarios to obtain the smallest sample size that provided a statistically signifi-
cant minimum clinically meaningful QALY difference between the treatments. 
Simulations were performed (e.g. testing the effect of different survival profile sce-
narios, utility values) to assess the robustness of the results. cOnclusiOns: The 
presented trial simulation model provided a flexible tool to inform clinical trial 
design considering QoL outcomes. The model can be also useful for manufacturers 
for pricing or investment decisions.
PRM96
SYSTEMATIC REVIEW OF MATHEMATICAL MODELS PREDICTING RELATIVE 
EFFECTIVENESS
Hummel N., Panayidou K., Gsteiger S., Egger M., Kilcher G.
University of Bern, Bern, Switzerland
Objectives: To identify and assess mathematical models predicting the relative 
effectiveness of drug treatments in “real world” populations, based on data from 
randomized control trials and other sources of evidence. MethOds: Systematic 
review of mathematical modelling studies addressing the step from relative effi-
cacy to relative effectiveness. We identified eligible studies through electronic and 
manual searches of MEDLINE and EMBASE databases, selected websites and refer-
ence lists of relevant papers. Two reviewers screened the articles independently 
and extracted study characteristics such as model type, disease area, validation 
and software used via an extraction form. Results: Eight papers met the inclusion 
criteria covering four broad modelling approaches: multi-state models, simulation-
based approaches, mechanistic models, and classical regression based models. The 
multi-state models were the predominant class of models. These models are defined 
as time-dependent stochastic processes with discrete event space. Most examples 
belonged to the special case of Markov multi-state models. Multi-state models 
were applied at the level of population groups or at the individual patient level. 
The other approaches we identified were less frequent. Discrete event simulation 
was used in one paper. This approach is entirely based on simulations. One article 
described a mechanistic model based on ordinary differential equations, which 
are typically derived from biological knowledge and first principles. Finally, more 
classical regression techniques from survival analysis were used in two papers. Six 
articles included models built for cardiovascular indications, the remaining ones 
covered oncology and neurosciences. Internal or external model validation was 
presented in six papers, while two papers considered only sensitivity analysis to 
evaluate the model performance. cOnclusiOns: This review shows the range of 
models currently used for predicting the relative effectiveness of drug interventions 
in real world patient populations. They complement the available tools for evidence 
synthesis in comparative effectiveness research.
PRM97
COST-EFFECTIVENESS ANALYSIS OF AN ANTIMICROBIAL TRANSPARENT 
DRESSING FOR PROTECTING CENTRAL VASCULAR ACCESSES IN CRITICALLY 
ILL PATIENTS VERSUS STANDARD TRANSPARENT DRESSINGS IN FRANCE: A 
COMPARISON OF TWO MODELING APPROACHES: DECISION-TREE VERSUS NON-
HOMOGENEOUS MARkOV MODEL
Palka-Santini M.1, Motrunich A.2, Maunoury F.2
13M Germany, Neuss, Germany, 2Statésia, Le Mans, France
Objectives: To perform cost-effectiveness analysis (CEA) for routine use of a trans-
parent dressing integrating a chlorhexidine gluconate (CHG) -containing gel pad 
versus standard transparent dressings, with a classical decision tree model and 
a Non-Homogeneous Markov Model (NHMM) previously developed. MethOds: 
Clinical efficacy data was extracted from a multicentre randomized controlled trial 
(RCT) with 1,879 patients and economical data obtained from micro and macro-
costing published studies. The baseline method is a NHMM previously developed in 
Microsoft Excel® with VBA using the same data sources. The decision tree was built 
with the TreeAge Pro® software 2013. One-way deterministic (DSA) and probabilistic 
sensitivity (PSA) analyses were conducted on key clinical and economic param-
eters. Results: Based on the decision-tree model, the CHG-dressing is a dominant 
strategy compared to standard dressings. The intervention prevents 13.5 infections 
per 1,000 patients and saves € 157 per patient. These results are robust across a 
range of values for several parameters in DSA. The PSA with the NHMM resulted in 
11.8 infections avoided per 1,000 patients (95%CI: [3.85; 19.64)]) and a mean extra 
cost of € 141 per patient (95%CI: [€ -975; € 1,258]) when using antimicrobial dress-
ing. Effectiveness as calculated by both models is similar while cost estimations 
diverge. cOnclusiOns: Decision-tree and the NHMM are structurally different and 
even though their outcomes cannot be directly compared, they were coherent. The 
decision-tree model indicates that CHG-dressings are cost-saving and a dominant 
preventative strategy for CRBSIs. The Markov model supports cost-effectiveness 
compared to standard dressing. The main disadvantages of the decision-tree are the 
inability to integrate changes among health states during the ICU stay and to simu-
late possible observable trajectories in the patient history. The structure of the non-
homogeneous Markov model does not allow DSA for the incidence of the disease.
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losses, and informal care. Specific parameters to be entered by users are the preva-
lence of the mutation, treatment costs, specificity/sensitivity and cost of the test, 
survival data and the incidence of AEs. cOnclusiOns: The proposed global model 
for the economic evaluation of targeted treatments using companion diagnostics in 
advanced/metastatic cancer treatment can, with minimal input, quickly generate 
cost-effectiveness analyses of targeted cancer treatment.
PRM104
A WEB BASED OPTIMISATION MODEL FOR A PORTFOLIO OF PREVENTATIVE 
INTERVENTIONS UTILIzING MULTI CRITERIA DECISION ANALYSES (MCDA) 
FRAMEWORk
Topachevskyi O.1, Volovyk A.2
1Digital Health Outcomes, Brussels, Belgium, 2Hashtago, Kiev, Ukraine
Objectives: To inform decision makers who seek extension of Universal Mass 
Vaccination (UMV) about the most optimal allocation of funds across multiple pre-
ventative interventions or vaccines. To account for decision makers preferences using 
MCDA. MethOds: A multi cohort markov model was developed to assess clinical and 
economic consequences of vaccine preventable diseases in Japan. Disease incidence 
rates, direct medical costs and QoL data were obtained from local sources. Payer 
perspective only was considered. Optimization module utilizing linear programming 
was developed to maximize outcome of interest which serve as an objective function 
subject to budget and intervention coverage constraints. A working version of the 
model can be found at http: //www. digitalho. com/models/a/portfolio/index. html. 
The model was initially developed in Excel and then automatically transformed into 
a JavaScript application to allow for an online access. One way sensitivity analyses 
was conducted to parametric unceranity. Results: Model results indicate that the 
optimal mix of interventions depends primarily on the objective function. Various 
single objective functions or a combination of multiple weighted objectives lead to 
different mix of interventions. When prevention of death is as an objective function 
then pneumococcal and rotavirus vaccines are chosen. cOnclusiOns: The proposed 
web based model is a complementary addition to the conventional cost-effectiveness 
assessment for preventative interventions. This model helps to understand sequence 
of introduction of prevantative interventions and expected health and economic 
outcomes over time. The use of MCDA framework helps users to define specfic health 
objectives to be used in optimisation module. The web based modeling solution pro-
vides a widespread access to an easy to use tool that can by used by authorities, 
academia and non-modeling professionals.
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Objectives: For the evaluation of the potential cost-effectiveness of an early 
experimental therapy, we calibrated an existing micro-simulation model for radio-
therapy planning in lung cancer using pilot data. MethOds: We used an exter-
nally validated micro-simulation model, build using Real World Evidence data. 
The model contained four clinical states from alive to death, with intermediate 
states ‘local recurrence’ and ‘metastasis’, with 5 transitions. Based on individual 
and time-dependent hazard rates, patients move through the model according to 
their combination of patient characteristics and random variation. For the experi-
mental dosis-escalation therapy we had limited pilot study data, which included 
overall survival and a number of baseline characteristics. The distribution of patient 
features in the cohort of the micro-simulation model was adjusted so that the simu-
lated patients had the same baseline characteristics as the patients that received 
experimental therapy. Alternative radiotherapy strategies affected 5 transitions in 
the model, quantified by 5 hazard ratios (HRs). Subsequently, HRs for experimental 
radiotherapy compared to current radiotherapy were calibrated until they were 
able to satisfactorily reproduce the survival curve of the pilot data. The best fitting 
sets of HRs were selected based on the least Sum of Squared Errors (SSE) of the 
model predictions and the survival curve of the experimental therapy on three 
time points. Results: The best fitting set HRs resulted in a SSE of 0,005 based on 
prediction errors at 1,2 and 3-year survival. Although 33 out of 1000 sets produced 
predictions with less than 5% prediction error, hazard ratios varied strongly within 
and over the different sets. cOnclusiOns: By using calibration, we obtained a 
micro-simulation model that is suitable for the evaluation of new treatments in 
the absence of empirical data. The model will be used for cost-effectiveness analy-
ses, where the variation in hazard ratios within sets will be evaluated in scenario 
analyses.
PRM106
HOW DOES UNCERTAINTY AROUND COSTS AND EFFECTS RELATE TO 
UNCERTAINTY AROUND COST-EFFECTIVENESS?
Jain M.1, Bhattacharyya S.1, Gupta S.1, Sonathi V.1, Mahon R.2, Malakar H.1, Vudumala U.1, 
Gunda P.1, Kumar P.1, Partha G.1, Thomas S.K.3
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Ireland Limited, Dublin, Ireland, 
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: HTAs require information on costs and outcomes as well as the 
uncertainty around them for making reimbursement decisions. Uncertainty 
around costs and effects (outcome uncertainty) can be substantial and increas-
ingly so at more distal time points. However, the uncertainty surrounding the 
decision to adopt or reject a technology based on cost-effectiveness (decision 
uncertainty) evolves over time in a different manner. In this analysis, we intend 
to illustrate that increased outcome uncertainty need not result in increased 
decision uncertainty and that both may evolve over time differently. MethOds: 
A previously published lifetime Markov model, built from UK health care perspec-
tive, was used in the analysis. The model compared the cost-effectiveness (CE) of 
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APPLICATION OF A MODEL OF DECISION BASED ON FUzzY LOGIC TO 
PHARMACOECONOMICS: RANIBIzUMAB VERSUS AFLIBERCERT IN AMD
Alonso Herreros J.M.1, González-Cuello A.2
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Objectives: The term “fuzzy logic” was introduced in 1965 by LAZadeh. Compared 
to traditional logic, fuzzy logic variables may have a truth value in degree. Fuzzy 
logic has been applied to many fields, from economic analysis, to artificial intel-
ligence. However it has not been applied so far to pharmacoeconomics. We present a 
model of pharmacoeconomic decision based on fuzzy logic (Fuzzy Economic Review 
2001; 6 (2): 51-73) and applied to the selection of ranibizumab-aflibercept in treating 
AMD. MethOds: According to a decision analysis model based on fuzzy logic four 
fuzzy variables that affect the choice of treatment are defined: treatment success 
(expressed as a probability), cost of success, cost of failure (expressed as inverses), 
and other conditions about the cost (negotiation, handling of drugs...). Based on 
the value of these fuzzy variables, three linguistic variables (High, Medium, Low) 
are defined to expressing convenience of choice. The combination of the three pos-
sible values for each of the variables gives us 81 possible decision rules, so that the 
(HHHH) would be the most favorable option and (LLLL) the more unfavorable. So 
a new fuzzy variable called “ranking” is established for classifying these options 
with 7 possible values (Very-unfavorable, unfavorable, slightly-unfavorable, neutral, 
slightly-favorable, favorable, very-favorable). The value of the fuzzy variables for 
ranibizumab and aflibercept were established based on pivotal clinical trials at 52 
weeks cited by the EMEA. Results: The matrices obtained for ranibizumab was 
(0.29,3. 55 10-4, -1.36 10-4 0.7), and aflibercept (0.269,7. 4 10-4 -2.59 10-4 0.3). These 
matrices correspond to decision rules (HLLM) and (HMML) and correspond to a 
ranking of “neutral” and “slightly-favorable”. cOnclusiOns: It possible to apply 
methods of “fuzzy logic” to pharmacoeconomic studies to select the most favorable 
treatment. According to model, AMD treatment, with aflibercept would be a slightly 
more favorable option than ranibizumab.
PRM102
DEVELOPMENT OF AN INFLUENzA OUTBREAk FORECASTING MODEL USING 
TIME SERIES ANALYSIS METHODS
Smolen H.J.
Medical Decision Modeling Inc., Indianapolis, IN, USA
Objectives: To use historical influenza incidence time series data to develop a 
predictive model using time series analysis methods to forecast expected num-
ber of reported influenza cases. bAcKGROund: Influenza is a common disease 
associated with high mortality. Low vaccination rates motivate health officials to 
predict outbreaks and intervene accordingly. A predictive model would facilitate in 
deciding whether an apparent excess of cases represents an outbreak or a random 
variation. MethOds: Google Flu Trend project data from 2003 to 2014 was used to 
construct this predictive model. The influenza time series data clearly had a sea-
sonal variation to it so a seasonally fit model using seasonal indicators, a seasonally 
fit model using trigonometric functions, and a multiplicative seasonal autoregres-
sive integrated moving average (SARIMA) model were considered. Fifty-two weeks 
of data from the time series were withheld from the model fitting process so as 
to evaluate the predictive capability of the selected model using mean absolute 
percentage error (MAPE). The Akaike’s Information Criterion (AIC) goodness of fit 
measure was used to select the model that fit the data the best (lower the bet-
ter). Results: The SARIMA model provided the best fit for the data with an AIC of 
6361.7. The seasonally fit model using seasonal indicators had an AIC of 8473.9 and 
the seasonally fit model using trigonometric functions had an AIC of 8438.2. The 
SARIMA model MAPE for the predicted 52 weeks was 87.5%. The forecasted values 
were within the 95% confidence band of the actual ending 52 week data, though at 
the high end of the band. cOnclusiOns: The SARIMA model was an appropriate 
predictor for flu cases in 2013-4. The data used to construct the model included flu 
epidemics so removing these time periods would result in a model more appropri-
ate for non-epidemic periods.
PRM103
DEVELOPMENT OF A GLOBAL ECONOMIC MODEL TO EVALUATE THE COST-
EFFECTIVENESS OF TARGETED TREATMENTS USING COMPANION DIAGNOSTICS 
IN ADVANCED/METASTATIC CANCER TREATMENT
Mathurin K., Beauchemin C., Lachaine J.
University of Montreal, Montreal, QC, Canada
Objectives: With the development of high priced new targeted treatment for can-
cer, there is a need to know as soon as possible if these treatments are likely to 
be cost-effective. The objective of this study was to develop a model with global 
parameters to estimate the cost-effectiveness of targeted treatments using compan-
ion diagnostics in advanced/metastatic cancer treatment. MethOds: The model 
was developed to take into account parameters usually considered in conventional 
economic models in cancer (treatment costs, costs of cancer care, target population 
characteristics, survival data, utilities, disutilities and costs associated with adverse 
events (AEs), etc.), and also parameters specific to the companion diagnostic itself 
(mutation prevalence, test specificity and sensitivity, and cost). The model had to 
allow performing cost-utility analyses from both a Health Ministry and a societal 
perspective and for most common cancers (lung, breast, colorectal, prostate, cer-
vical/endometrial, bladder, and non-Hodgkin’s lymphoma). Results: The global 
model comprises a decision tree and a lifetime Markov model. The decision tree 
takes into account the sensitivity and specificity and cost of the companion diag-
nosis, and the prevalence of the biomarker/mutation in the eligible population. 
The Markov model with monthly cycles includes the following 3 health states: 
progression-free, progressive disease and death. Intrisic parameters of the model 
comprise the mean characteristics of the target population, utilities associated 
with health states, disutilities and costs associated with AEs, and costs associated 
with drug administration, cancer care, end-of-life care, follow-up visits, productivity 
